Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being reassured everything is fine.

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

A research team led by Prof. Gu Hongcang from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...

The National Institute for Health and Care Excellence (NICE) has recommended brentuximab vedotin combined with doxorubicin, ...

Experts discuss the 5-year efficacy and safety outcomes of polatuzumab in diffuse large B-cell lymphoma (DLBCL), highlighting ...

NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda.

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.